UV-visible absorption spectroscopy for in-line API concentration measurement in nanoparticle production process using controlled expansion of supercritical solutions (CESS®).
Active pharmaceutical ingredient
Controlled expansion of supercritical solutions
Nanoparticle production
Process analytical technology
Solute concentration
Ultraviolet-visible spectroscopy
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
05 Feb 2023
05 Feb 2023
Historique:
received:
26
09
2022
revised:
15
11
2022
accepted:
16
11
2022
pubmed:
4
12
2022
medline:
7
1
2023
entrez:
3
12
2022
Statut:
ppublish
Résumé
Most new small drug molecules in pharmaceutical development require improvement of solubility. The controlled expansion of supercritical solutions (CESS®) process is a nanoparticle production technology, dedicated to enhancing the dissolution rate of active pharmaceutical ingredients (APIs) suffering from poor solubility and enabling novel drug delivery opportunities. In this process, the API is dissolved in supercritical carbon dioxide (scCO
Identifiants
pubmed: 36462249
pii: S0731-7085(22)00590-8
doi: 10.1016/j.jpba.2022.115169
pii:
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115169Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ari Kauppinen reports a relationship with Nanoform Finland Plc that includes: employment. Petteri Helander reports a relationship with Nanoform Finland Plc that includes: employment. Mikael Viitala reports a relationship with Nanoform Finland Plc that includes: employment. Tuomas Puranen reports a relationship with Nanoform Finland Plc that includes: employment. Tuomas Vainikka reports a relationship with Nanoform Finland Plc that includes: employment. Ilkka Lassila reports a relationship with Nanoform Finland Plc that includes: employment and equity or stocks. Edward Hæggström reports a relationship with Nanoform Finland Plc that includes: employment and equity or stocks. Niklas Sandler reports a relationship with Nanoform Finland Plc that includes: employment and equity or stocks. Edward Hæggström has patent A method and a device for producing nanoparticles issued to Nanoform Finland Oy. Ilkka Lassila has patent A method and a device for producing nanoparticles issued to Nanoform Finland Oy.